Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

LifeTime and Dovetail enter exclusive agreement for Beta LT anticancer compound

June 8, 1999

AVI BioPharma to initiate phase II clinical trial of Avicine in pancreatic cancer

June 7, 1999

Additional phase II data suggest modifications for AVI BioPharma's cancer vaccine

June 1, 1999

Phase II trial of York Medical's cancer vaccine cleared

June 1, 1999

Ilex reports progress on Campath development at annual meeting

May 31, 1999

Encouraging phase I trials results for Prostvac presented at ASCO

May 27, 1999

Antiidiotype cancer vaccine induces immune response and may delay disease progression in MBC

May 27, 1999

Maxim completes first two marketing agreements for Maxamine

May 27, 1999

Additional findings announced for Avax Technologies' cancer vaccine

May 27, 1999

Humanized antibody-cytokine fusion protein demonstrates immunological activity in phase I trial

May 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...